Inhibition of human cervical carcinoma growth by cytokine-induced killer cells in nude mouse xenograft model

International Immunopharmacology

Volumn 9, Issue 3, 2009, Pages 375-380

  Kim, Hwan Mook ^a   Lim, Jaeseung ^b   Kang, Jong Soon ^a   Park, Song Kyu ^a   Lee, Kiho ^a   Kim, Jee Youn ^c   Kim, Yeon Jin ^c   Hong, Jin Tae ^c   Kim, Youngsoo ^c   Han, Sang Bae ^c  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Innocell Ltd   (South Korea)

^c Chungbuk National University   (South Korea)

Author keywords

Adoptive immunotherapy; Cytokine induced killer cells; KB 3 1 cervical cancer

Indexed keywords

CD3 ANTIBODY; CD56 ANTIGEN; CHROMIUM 51; CYTOKINE; INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CD4+ T LYMPHOCYTE; CELL DESTRUCTION; CELL POPULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; INCUBATION TIME; KILLER CELL; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA; XENOGRAFT;

ANIMALS; CARCINOMA; CELL LINE, TUMOR; CYTOKINE-INDUCED KILLER CELLS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; MICE; MICE, NUDE; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 60549107530     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.12.001     Document Type: Article

References (43)

1. Franco E.L., Schlecht N.F., and Saslow D. The epidemiology of cervical cancer. Cancer J 9 (2003) 348-359
2. Garcia F.A., and Saslow D. Prophylactic human papillomavirus vaccination: a breakthrough in primary cervical cancer prevention. Obstet Gynecol Clin North Am 34 (2007) 761-781
3. Saslow D., and Wheeler C.M. Human papillomavirus vaccines: who will pay, who will receive, when to administer?. Ethn Dis 17 (2007) S2-8-13
4. Peters III W.A., Liu P.Y., Barrett II R.J., Stock R.J., Monk B.J., Berek J.S., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18 (2000) 1606-1613
5. Rose P.G., Bundy B.N., Watkins E.B., Thigpen J.T., Deppe G., Maiman M.A., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340 (1999) 1144-1153
6. Whitney C.W., Sause W., Bundy B.N., Malfetano J.H., Hannigan E.V., Fowler Jr. W.C., et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 17 (1999) 1339-1348
7. Lu P.H., and Negrin R.S. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 153 (1994) 1687-1696
8. Thorne S.H., Negrin R.S., and Contag C.H. Synergistic antitumor effects of immune cell-viral biotherapy. Science 311 (2006) 1780-1784
9. Verneris M.R., Karami M., Baker J., Jayaswal A., and Negrin R.S. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 103 (2004) 3065-3072
10. Edinger M., Cao Y.A., Verneris M.R., Bachmann M.H., Contag C.H., and Negrin R.S. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 101 (2003) 640-648
11. Kim H.M., Lim J., Yoon Y.D., Ahn J.M., Kang J.S., Lee K., et al. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma. Int Immunopharmacol 7 (2007) 1793-1801
12. Takayama T., Sekine T., Makuuchi M., Yamasaki S., Kosuge T., Yamamoto J., et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356 (2000) 802-807
13. Kornacker M., Moldenhauer G., Herbst M., Weilguni E., Tita-Nwa F., Harter C., et al. Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma. Int J Cancer 119 (2006) 1377-1382
14. Kim H.M., Lim J., Park S.K., Kang J.S., Lee K., Lee C.W., et al. Antitumor activity of cytokine-induced killer cells against human lung cancer. Int Immunopharmacol 7 (2007) 1802-1807
15. Yang X.J., Huang J.A., Lei W., Zhu Y.B., and Zhang X.G. Antitumor effects of cocultured dendritic cells and cytokine-induced killer cells on lung cancer in vitro and in vivo. Ai Zheng 25 (2006) 1329-1333
16. Kim H.M., Kang J.S., Lim J., Park S.K., Lee K., Yoon Y.D., et al. Inhibition of human ovarian tumor growth by cytokine-induced killer cells. Arch Pharm Res 30 (2007) 1464-1470
17. Wang W., Epler J., Salazar L.G., and Riddell S.R. Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1. Cancer Res 66 (2006) 6826-6833
18. Sun S., Li X.M., Li X.D., and Yang W.S. Studies on inducing apoptosis effects and mechanism of CIK cells for MGC-803 gastric cancer cell lines. Cancer Biother Radiopharm 20 (2005) 173-180
19. Han S.B., Lee C.W., Jeon Y.J., Hong N.D., Yoo I.D., Yang K.H., et al. The inhibitory effect of polysaccharides isolated from Phellinus linteus on tumor growth and metastasis. Immunopharmacology 41 (1999) 157-164
20. Han S.B., Moratz C., Huang N.N., Kelsall B., Cho H., Shi C.S., et al. Rgs1 and Gnai2 regulate the entrance of B lymphocytes into lymph nodes and B cell motility within lymph node follicles. Immunity 22 (2005) 343-354
21. Kim J.Y., Yoon Y.D., Ahn J.M., Kang J.S., Park S.K., Lee K., et al. Angelan isolated from Angelica gigas Nakai induces dendritic cell maturation through toll-like receptor 4. Int Immunopharmacol 7 (2007) 78-87
22. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
23. Edwards R.P., Pitts A., Crowley-Nowick P., Partridge E.E., Gore H., and Mestecky J. Immunoglobulin-containing plasma cells recruited to cervical neoplasia. Obstet Gynecol 87 (1996) 520-526
24. Evans E.M., Man S., Evans A.S., and Borysiewicz L.K. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 57 (1997) 2943-2950
25. Arias-Pulido H., Joste N., and Wheeler C.M. Loss of heterozygosity on chromosome 6 in HPV-16 positive cervical carcinomas carrying the DRB1*1501-DQB1*0602 haplotype. Genes Chromosomes Cancer 40 (2004) 277-284
26. O'Brien P.M., and Campo M.S. Papillomaviruses: a correlation between immune evasion and oncogenicity?. Trends Microbiol 11 (2003) 300-305
27. de Jong A., van der Burg S.H., Kwappenberg K.M., van der Hulst J.M., Franken K.L., Geluk A., et al. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 62 (2002) 472-479
28. de Jong A., van Poelgeest M.I., van der Hulst J.M., Drijfhout J.W., Fleuren G.J., Melief C.J., et al. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 64 (2004) 5449-5455
29. Nakagawa M., Stites D.P., Patel S., Farhat S., Scott M., Hills N.K., et al. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J Infect Dis 182 (2000) 595-598
30. Ghosh A.K., and Moore M. Tumour-infiltrating lymphocytes in cervical carcinoma. Eur J Cancer 28A (1992) 1910-1916
31. Sheu B.C., Hsu S.M., Ho H.N., Lien H.C., Huang S.C., and Lin R.H. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 61 (2001) 237-242
32. Sheu B.C., Lien H.C., Ho H.N., Lin H.H., Chow S.N., Huang S.C., et al. Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res 63 (2003) 6537-6542
33. Sheu B.C., Lin R.H., Lien H.C., Ho H.N., Hsu S.M., and Huang S.C. Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. J Immunol 167 (2001) 2972-2978
34. Steele J.C., Mann C.H., Rookes S., Rollason T., Murphy D., Freeth M.G., et al. T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia. Br J Cancer 93 (2005) 248-259
35. Kalinski P., Nakamura Y., Watchmaker P., Giermasz A., Muthuswamy R., and Mailliard R.B. Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines. Immunol Res 36 (2006) 137-146
36. Raja Gabaglia C., Diaz de Durana Y., Graham F.L., Gauldie J., Sercarz E.E., and Braciak T.A. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors. Cancer Res 67 (2007) 2290-2297
37. Takashima K., Fujiwara H., Inada S., Atsuji K., Araki Y., Kubota T., et al. Tracking of green fluorescent protein (GFP)-labeled LAK cells in mice carrying B16 melanoma metastases. Anticancer Res 26 (2006) 3327-3332
38. Schmidt-Wolf I.G., Negrin R.S., Kiem H.P., Blume K.G., and Weissman I.L. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174 (1991) 139-149
39. Grabert R.C., Cousens L.P., Smith J.A., Olson S., Gall J., Young W.B., et al. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clin Cancer Res 12 (2006) 569-576
40. Alvarnas J.C., Linn Y.C., Hope E.G., and Negrin R.S. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 7 (2001) 216-222
41. Baker J., Verneris M.R., Ito M., Shizuru J.A., and Negrin R.S. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood 97 (2001) 2923-2931
42. Han S.B., Lee C.W., Yoon Y.D., Kang J.S., Lee K.H., Yoon W.K., et al. Effective prevention of lethal acute graft-versus-host disease by combined immunosuppressive therapy with prodigiosin and cyclosporine A. Biochem Pharmacol 70 (2005) 1518-1526
43. Leemhuis T., Wells S., Scheffold C., Edinger M., and Negrin R.S. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 11 (2005) 181-187